secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-119077
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports Q3 2024 net loss of $2.3M; receives $4M NIH grants
------------------------------------------------------------------------------

- Cash and cash equivalents of $9.0M as of Sept 30, 2024; expects to fund operations into October 2025.
- Net loss from continuing operations improved to $2.3M (Q3 2024) from $3.0M (Q3 2023).
- R&D expenses rose to $3.5M (Q3 2024) vs $2.0M (Q3 2023) due to increased clinical trial activity.
- Received two $2M SBIR grants from NIH ($4M total) to support MT-601 trials in lymphoma and pancreatic cancer.
- Phase 1 APOLLO study of MT-601 in lymphoma continues enrolling; expects preliminary data by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/0001104659-24-119077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/tm2421372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer